MBX Biosciences, Inc. filed a Form S-1 registration statement for an initial public offering on 2024-08-23. It has amended it 2 times. It filed its final prospectus on 2025-09-25, at a public offering price of $18.00 per share. Each fact below is quoted from the filing named with it.
What the filings say
Listing
Our common stock is listed on the Nasdaq Global Select Market, or Nasdaq, under the symbol “MBX”.From the 424B4 filed 2025-09-25
Shares offered
We are offering 11,108,055 shares of our common stock.From the 424B4 filed 2025-09-25
Offering price
the public offering price of $18.00 per share;From the 424B4 filed 2025-09-25
Underwriters
Morgan Securities LLC and Jefferies LLC are acting as joint book-running managers of the offering, and as representatives of the underwriters.From the 424B4 filed 2025-09-25
Use of proceeds
We intend to use the net proceeds of this offering, together with our existing cash and cash equivalents and short-term investments, to fund the continued development of canvuparatide, imapextide, and MBX 4291, as well as our other obesity preclinical stage program, our discovery research and development activities and additional clinical development and for general corporate purposes and working capital.From the 424B4 filed 2025-09-25
Net loss or income
Our net loss was $26.1 million and $32.6 million for the years ended December 31, 2022 and 2023, respectively.From the S-1/A filed 2024-09-09
Timeline
| Filed | What it is | Filing |
|---|---|---|
| 2024-08-23 | Registration statement filed | S-1 |
| 2024-08-30 | Registration statement amended | S-1/A |
| 2024-09-09 | Registration statement amended | S-1/A |
| 2025-09-22 | Registration statement filed | S-1 |
| 2025-09-25 | Final prospectus filed: the offering is priced | 424B4 |
Tools for this story
Each opens in a new tab, filled in for MBX Biosciences, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A company that wants to sell shares to the public in the United States files a registration statement with the SEC: Form S-1 for a US company, Form F-1 for a foreign one. It amends that statement as the figures and terms are filled in, usually adding the expected price range shortly before the offering. Once the offering is priced it files its final prospectus under Rule 424(b)(4). A company that decides not to go ahead can ask for the registration statement to be withdrawn on Form RW.
Every row on this page is one of those filings, linked to the filing itself. The facts are the company's own sentences, quoted from the filing named beside each one and never reworded; where no filing states a fact in a sentence that can be read exactly, this page leaves it out. A filing is the company's statement of its plans and its figures, not a verification of them, and nothing here is investment advice.